209 related articles for article (PubMed ID: 37673901)
21. Crystal structure of the M
Vuckovic Z; Gentry PR; Berizzi AE; Hirata K; Varghese S; Thompson G; van der Westhuizen ET; Burger WAC; Rahmani R; Valant C; Langmead CJ; Lindsley CW; Baell JB; Tobin AB; Sexton PM; Christopoulos A; Thal DM
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):26001-26007. PubMed ID: 31772027
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and evaluation of novel 2-phenyl-3-(1H-pyrazol-4-yl)pyridine positive allosteric modulators for the M
Jörg M; van der Westhuizen ET; Lu Y; Christopher Choy KH; Shackleford DM; Khajehali E; Tobin AB; Thal DM; Capuano B; Christopoulos A; Valant C; Scammells PJ
Eur J Med Chem; 2023 Oct; 258():115588. PubMed ID: 37423123
[TBL] [Abstract][Full Text] [Related]
23. Positive allosteric modulation of M
Yohn SE; Conn PJ
Neuropharmacology; 2018 Jul; 136(Pt C):438-448. PubMed ID: 28893562
[TBL] [Abstract][Full Text] [Related]
24. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
[TBL] [Abstract][Full Text] [Related]
25. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.
Yohn SE; Weiden PJ; Felder CC; Stahl SM
Trends Pharmacol Sci; 2022 Dec; 43(12):1098-1112. PubMed ID: 36273943
[TBL] [Abstract][Full Text] [Related]
26. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.
Valant C; Felder CC; Sexton PM; Christopoulos A
Mol Pharmacol; 2012 Jan; 81(1):41-52. PubMed ID: 21989256
[TBL] [Abstract][Full Text] [Related]
27. Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.
Sheffler DJ; Sevel C; Le U; Lovell KM; Tarr JC; Carrington SJ; Cho HP; Digby GJ; Niswender CM; Conn PJ; Hopkins CR; Wood MR; Lindsley CW
Bioorg Med Chem Lett; 2013 Jan; 23(1):223-7. PubMed ID: 23200253
[TBL] [Abstract][Full Text] [Related]
28. Structural Features of Iperoxo-BQCA Muscarinic Acetylcholine Receptor Hybrid Ligands Determining Subtype Selectivity and Efficacy.
Wakeham MCL; Davie BJ; Chalmers DK; Christopoulos A; Capuano B; Valant C; Scammells PJ
ACS Chem Neurosci; 2022 Jan; 13(1):97-111. PubMed ID: 34905693
[TBL] [Abstract][Full Text] [Related]
29. The structural study of mutation-induced inactivation of human muscarinic receptor M4.
Wang J; Wu M; Wu L; Xu Y; Li F; Wu Y; Popov P; Wang L; Bai F; Zhao S; Liu ZJ; Hua T
IUCrJ; 2020 Mar; 7(Pt 2):294-305. PubMed ID: 32148857
[TBL] [Abstract][Full Text] [Related]
30. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission.
Shirey JK; Xiang Z; Orton D; Brady AE; Johnson KA; Williams R; Ayala JE; Rodriguez AL; Wess J; Weaver D; Niswender CM; Conn PJ
Nat Chem Biol; 2008 Jan; 4(1):42-50. PubMed ID: 18059262
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1).
Bonifazi A; Yano H; Del Bello F; Farande A; Quaglia W; Petrelli R; Matucci R; Nesi M; Vistoli G; Ferré S; Piergentili A
J Med Chem; 2014 Nov; 57(21):9065-77. PubMed ID: 25275964
[TBL] [Abstract][Full Text] [Related]
32. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
Christopoulos A; Pierce TL; Sorman JL; El-Fakahany EE
Mol Pharmacol; 1998 Jun; 53(6):1120-30. PubMed ID: 9614217
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
[TBL] [Abstract][Full Text] [Related]
34. The antipsychotic potential of muscarinic allosteric modulation.
Bridges TM; LeBois EP; Hopkins CR; Wood MR; Jones CK; Conn PJ; Lindsley CW
Drug News Perspect; 2010 May; 23(4):229-40. PubMed ID: 20520852
[TBL] [Abstract][Full Text] [Related]
35. The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor.
Leach K; Davey AE; Felder CC; Sexton PM; Christopoulos A
Mol Pharmacol; 2011 May; 79(5):855-65. PubMed ID: 21300722
[TBL] [Abstract][Full Text] [Related]
36. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
Teal LB; Gould RW; Felts AS; Jones CK
Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
[TBL] [Abstract][Full Text] [Related]
37. Allosteric binding sites on muscarinic acetylcholine receptors.
Wess J
Mol Pharmacol; 2005 Dec; 68(6):1506-9. PubMed ID: 16183853
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M
van der Westhuizen ET; Spathis A; Khajehali E; Jörg M; Mistry SN; Capuano B; Tobin AB; Sexton PM; Scammells PJ; Valant C; Christopoulos A
Mol Pharmacol; 2018 Jul; 94(1):770-783. PubMed ID: 29691279
[TBL] [Abstract][Full Text] [Related]
39. Tacrine-xanomeline and tacrine-iperoxo hybrid ligands: Synthesis and biological evaluation at acetylcholinesterase and M
Maspero M; Volpato D; Cirillo D; Yuan Chen N; Messerer R; Sotriffer C; De Amici M; Holzgrabe U; Dallanoce C
Bioorg Chem; 2020 Mar; 96():103633. PubMed ID: 32032848
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA
Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
